secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0000950170-25-102027
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics Q2 net loss $208.5M; CASGEVY hits 75 ATCs, 115 cell collections; CTX310 shows 86% LDL reduction
--------------------------------------------------------------------------------

- Net loss of $208.5M in Q2 2025 vs $126.4M in Q2 2024; cash & securities $1.72B down from $1.90B at end-2024.
- CASGEVY momentum: >75 authorized treatment centers activated, ~115 patients had cells collected, 29 received infusions (16 in Q2).
- CTX310 Phase 1 data: dose-dependent TG reduction up to 82% and LDL reduction up to 86% after single administration; full data H2 2025.
- EMA authorized Phase 2 trial for SRSD107 (Factor XI siRNA) in thromboembolic disorders; $25M upfront to partner Sirius Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017025102027/0000950170-25-102027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017025102027/crsp-20250804.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-102027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer